LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
Marina Chiara Garassino, Willemijn S.M.E. Theelen, Robert M. Jotte, Janessa Laskin, Filippo de Marinis, Carlos Aguado, Firas Badin, Izabela Chmielewska, Maximilian J. Hochmair, Shun Lu, Ernest Nadal, Gyula Ostoros, Enriqueta Felip, Alexander I. Spira, Conor M. Lane, Jinghua He, Richard C. Chao, Pasi A. Jänne
Topics & Concepts
MedicineDiscontinuationPembrolizumabAdverse effectInternal medicineLung cancerNauseaOncologyCancerImmunotherapyCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research Studies